The MVP Act is a top federal policy priority for AMCP. This important bipartisan bill will enhance Medicaid patient access to new, high-cost therapies by modernizing the framework for value-based purchasing arrangements.
On January 5, 2024, the Food and Drug Administration (FDA) issued a letter
authorizing the state of Florida’s Section 804 Importation Programs (SIP) proposal
(Authorization Letter).
Diabetes technology is the hardware, devices, and software that people with diabetes use to help manage their condition. Diabetes technology has expanded to include complex devices that both monitor blood sugar and deliver insulin. The American Diabetes Association now recommends use of continuous glucose monitoring (CGM) in individuals with both type 1 and type 2 diabetes. Rapid change in the diabetes technology landscape may lead to access barriers that can impact health plan programs, necessitating appropriate coverage policies.
The Office of the National Coordinator for Health Information Technology (ONC)
issued a final rule on Health Data, Technology, and Interoperability: Certification
Program Updates, Algorithm Transparency, and Information Sharing (Final Rule),
which is scheduled to be published in the Federal Register on Jan. 9, 2024.
AMCP Regulatory NewsBREAK: CMS Issues Letter to Plans and Pharmacy Benefit Managers
AMCP's most recent Partnership Forum drew participants from a range of backgrounds and perspectives to discuss the value of collaboration between health plans/payers and patient advocacy organizations in managed care pharmacy decision-making. Senior VP of Professional and Government Affairs Jennifer Mathieu shares key insights and takeaways from the event.
